Horizon Space Acquisition II Corp. $60M IPO Priced
Biotechnology
Initial Public Offering / IPO SPAC
Merger:
Jun 15, 2026
Industry:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Show Chart?
Load external content from TradingView!
*You can change or withdraw your consent at any time in the footer under Cookies.
Horizon Space Acquisition II Corp. Prices $60 Million Initial Public Offering
NEW YORK, NY, USA November 14, 2024 Horizon Space Acquisition II Corp., a blank check company incorporated in the Cayman Islands, announced the pricing of its initial public offering (IPO) of 6,000,000 units at $10.00 per unit. This offering is valued at $60 million and is intended to facilitate a business combination with one or more businesses or entities.
... Read on — Members only
About SL Science Holding Ltd
SL Bio is a biomedical company focused on developing innovative cellular and gene therapies for cancer treatment and regenerative medicine. Leveraging proprietary technologies and strategic partnerships, the company is advancing next-generation immunotherapies and exosome-based products for both medical and consumer applications. SL Bio’s approach combines scientific expertise with a commitment to improving patient outcomes and addressing unmet needs in healthcare. SL Bio also offers ISO-certified, dermatologically tested cow milk-derived exosome-based products and plant extract products for skin and hair care, with commercial distribution in Asia.
More SLBT News
Biotechnology
Initial Public Offering / IPO SPAC
Daily overview of upcoming SPAC and IPO events – from initial announcement to definitive agreement and public listing.
Discover last week’s SPAC and IPO highlights, key trends, and market updates. Stay informed with SpacStar.